Zhifei Bio's flu vaccine (ZFA02 adjuvant) cleared for trial

Chongqing Zhifei Biological Products Co., Ltd. (SZSE:300122) announced that its subsidiary, Anhui Zhifei Longcom Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of its trivalent influenza virus split vaccine (ZFA02 adjuvant). The trial will assess the vaccine's efficacy in preventing influenza caused by vaccine-related strains. The ZFA02 adjuvant is developed by Zhifei. The company anticipates the vaccine will offer an additional tool against seasonal influenza and complement its existing vaccine portfolio, including its already marketed quadrivalent influenza vaccine. Zhifei Bio also has a quadrivalent influenza vaccine in the late stages of production. Should the trials and subsequent approvals prove successful, this vaccine could significantly enhance Zhifei Bio's product offerings and market competitiveness in the influenza vaccine sector. The company cautioned investors regarding the uncertainties inherent in the clinical trial and regulatory approval processes.